Multiplex protein assay performance/evaluation and the requirement for precision and correlation to clinical assays

Clinical Chemistry and Laboratory Medicine

Volumn 49, Issue 11, 2011, Pages 1915-1918

  Phan, Kim ^a   Sohn, Kun Young ^a   Hill, Stephen A ^a   Worster, Andrew ^a   You, John ^a   Oremus, Mark ^a   Devereaux, Philip J ^a   Jaffe, Allan S ^b   Kavsak, Peter A ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b MAYO CLINIC   (United States)

Author keywords

Clinical platforms; Correlation; Matrix; Multiplex; Precision

Indexed keywords

CYTOKINE; FIBROBLAST GROWTH FACTOR RECEPTOR 1; INTERLEUKIN 6; PLACENTAL GROWTH FACTOR;

ACCURACY; HUMAN; LETTER; MULTIPLEX PROTEIN ASSAY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION;

BLOOD CHEMICAL ANALYSIS; BODY COMPOSITION; FEMALE; HUMANS;

EID: 80755171196     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2011.683     Document Type: Letter

References (11)

1. Kricka LJ, Master SR. Quality control and protein microarrays. Clin Chem 2009;55:1053-5.
2. Ellington AA, Kullo IJ, Bailey KR, Klee GG. Measurement and quality control issues in multiplex protein assays. Clin Chem 2009;55:1092-9.
3. Bea JW, Wright NC, Thompson P, Hu C, Guerra S, Chen Z. Performance evaluation of a multiplex assay for future use in biomarker discovery efforts to predict body composition. Clin Chem Lab Med 2011;49:817-24.
4. Kavsak PA, Lee A, Hirte H, Young E, Gauldie J. Cytokine elevations in acute coronary syndrome and ovarian cancer: a mechanism for the up-regulation of the acute phase proteins in these different disease etiologies. Clin Biochem 2008;41: 607-10.
5. Fu Q, Zhu J, Van Eyk JE. Comparison of mulitplex immunoassay platforms. Clin Chem 2010;56:314-8.
6. Kavsak PA, Ko DT, Newman AM, Palomaki GE, Lustig V, MacRae AR, et al. Risk stratification for heart failure and death in an acute coronary syndrome population using inflammatory cytokines and N-terminal pro-brain natriuretic peptide. Clin Chem 2007;53:2112-8. (Pubitemid 350197294)
7. Jelkmann W. Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin Chem 2011;47:617-23.
8. Kavsak PA, Hirte H, Hotte SJ. Vascular endothelial growth factor concentration as a predictive marker: ready for primetime? Clin Cancer Res 2010;16:1341.
9. Hochholzer W, Reichlin T, Stelzig C, Hochholzer K, Meissner J, Breidthardt T, et al. Impact of soluble fms-like tyrosine kinase-1 and placental growth factor serum levels for risk stratification and early diagnosis in patients with suspected acute myocardial infarction. Eur Heart J 2011;32:326-35.
10. National Committee for Clinical Laboratory Standards. Protocols for determination of limits of detection and limits of quantitation; approved guideline. NCCLS document EP17-A 2001. Wayne, PA: Clinical and Laboratory Standards Institute, 2001.
11. Kavsak PA, Newman AM, Ko DT, Macrae AR, Jaffe AS. The use of a cytokine panel to define the long-term risk stratification of heart failure/death in patients presenting with chest pain to the emergency department. Clin Biochem 2010;43:505-7.